The short answer
This page explains MASLD and MASH, the conditions once called fatty liver disease, and how they relate to liver cancer risk. It is general education, not individual medical advice.
MASLD is the newer name for nonalcoholic fatty liver disease, and MASH is the newer name for its inflammatory form, NASH.
NIDDK estimates about 24% of U.S. adults have this condition, and most have few or no symptoms.
The path toward liver cancer usually runs through MASH, then scarring called fibrosis, then cirrhosis.
Weight loss is the core treatment, and one medicine now has FDA accelerated approval for MASH with significant fibrosis.
On this page
Choose how you want to read this
The whole article, with every detail and caution.
Fatty liver disease now goes by a new name: MASLD, short for metabolic dysfunction-associated steatotic liver disease. Its more serious form, MASH, is what links this very common condition to liver cancer risk in a small share of people. The path is slow, it runs through liver scarring, and there are real levers to slow or stop it.
This page is for anyone told they have fatty liver, or who has risk factors for it. It decodes the new names, explains the path toward liver cancer, and covers the steps that can help.
The new names, decoded
NIDDK, the National Institutes of Health (NIH) institute for digestive and liver disease, explains the terms. Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver. It is also referred to as MASLD. It has two forms:
- Simple fatty liver (NAFL, also called MASL): fat in the liver with little or no inflammation or liver damage.
- NASH, also referred to as MASH: inflammation and liver damage, in addition to fat in the liver.
Same conditions, updated labels. You may see either set of names on test results and health pages for some time.
How common this is
Very. NIDDK reports that experts estimate about 24% of U.S. adults have NAFLD, and about 1.5% to 6.5% of U.S. adults have NASH. Roughly 10% of U.S. children ages 2 to 19 have NAFLD. NIDDK also notes that certain health conditions, including obesity, metabolic syndrome, and type 2 diabetes, make the condition more likely.
Most people will never know without testing. NIDDK calls it a silent disease with few or no symptoms.
The chain that leads toward liver cancer
The cancer connection is a chain, not a jump. NIDDK lays it out: the inflammation and liver damage of NASH can cause fibrosis, which is scarring of the liver. NASH may lead to cirrhosis, in which the liver is scarred and permanently damaged. Cirrhosis can lead to liver cancer.
NCI's liver cancer prevention summary says the same thing from the cancer side. It states that having NASH-related cirrhosis increases the risk of developing liver cancer.
Two points keep this in proportion. First, only a minority of people with fatty liver have the inflammatory MASH form. Second, the serious cancer risk concentrates in people whose livers have progressed to cirrhosis. The same NCI page covers hepatitis B and C and heavy alcohol use as other major risk factors.
Who gets monitored
Because the condition is silent, finding it usually starts with risk factors, not symptoms. If you have obesity, type 2 diabetes, or metabolic syndrome, ask your care team whether your liver has been checked and whether any follow-up testing applies to you. People found to have scarring or cirrhosis need a specific monitoring plan, and that plan should come from their own clinicians. What that looks like depends on how far the liver disease has gone.
The prevention levers
Weight loss is the core treatment. NIDDK is specific about the amounts. Losing at least 3% to 5% of body weight can reduce fat in the liver. Losing up to 7% to 10% may be needed to reduce liver inflammation and fibrosis. The route NIDDK recommends is healthy eating, portion control, and physical activity.
One medicine now has FDA approval. On March 14, 2024, FDA granted accelerated approval to resmetirom (Rezdiffra) for adults with noncirrhotic NASH with moderate to advanced fibrosis. NASH is the former name for MASH. It is used along with diet and exercise, and the approval is accelerated, meaning trials continue to confirm the benefit. Note that some NIDDK pages, written before this approval, still say no medicines have been approved. Whether any medicine fits your situation is a question for your care team.
Protect the liver from second hits. The other major liver cancer risk factors stack. NCI reports that chronic hepatitis C is the leading cause of liver cancer in North America. It also reports that heavy alcohol users who have cirrhosis are ten times more likely to develop liver cancer than heavy alcohol users without cirrhosis. Ask your team about hepatitis testing and vaccination, and see our pages on hepatitis B vaccination and alcohol and cancer risk.
What this means in practice
A fatty liver finding on a scan or blood test is common and is not a cancer diagnosis. It is a prompt to ask three questions: Is there inflammation or scarring? Which of my risk factors can we treat? What follow-up do I need, and when? The earlier those questions are asked, the more the answer is about prevention rather than treatment.
Sources
- NAFLD & NASH (MASLD & MASH) — National Institute of Diabetes and Digestive and Kidney Diseases
- Definition & Facts of NAFLD & NASH — NIDDK
- Treatment for NAFLD & NASH — NIDDK
- Liver (Hepatocellular) Cancer Prevention (PDQ) Patient Version — National Cancer Institute
- Drug Trials Snapshots: REZDIFFRA — U.S. Food and Drug Administration
Common questions
What is the difference between MASLD and MASH?
NIDDK describes two forms. In the simple form, there is fat in the liver with little or no inflammation or damage. In MASH, formerly NASH, there is inflammation and liver damage in addition to the fat. MASH is the form that can scar the liver over time.
Does fatty liver disease lead to liver cancer?
Most people with fatty liver have the simple form, but it can progress in some people. NIDDK explains the chain: MASH inflammation can cause fibrosis, MASH may lead to cirrhosis, and cirrhosis can lead to liver cancer. NCI likewise says NASH-related cirrhosis increases the risk of liver cancer.
How would I know I have it, if there are no symptoms?
NIDDK calls it a silent disease with few or no symptoms. It is often found through routine tests. If you have obesity, metabolic syndrome, or type 2 diabetes, ask your care team whether your liver has been assessed.
Is there a medicine for it?
In March 2024, FDA granted accelerated approval to resmetirom (Rezdiffra) for adults with noncirrhotic MASH, under its former name NASH, with moderate to advanced fibrosis. It is used along with diet and exercise. Weight loss remains the foundation of treatment, and whether any medicine fits you is a care-team decision.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Talk with a trained specialist or navigator
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Fever of 100.4°F (38°C) or higher during chemo, severe pain, or trouble breathing: call your cancer care team right away, day or night. Call 911 for an emergency.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-21 what this meansLast updated: 2026-08-21Next planned review: 2027-08-21
Review details and limits
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Words to know
Tap any term to see what it means.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.